Lisinopril Patent Expiration
Lisinopril is Used for treating acute myocardial infarction, hypertension, and heart failure. It was first introduced by Merck Research Laboratories Div Merck Co Inc
Lisinopril Patents
Given below is the list of patents protecting Lisinopril, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Qbrelis | US10039800 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US10265370 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US10406199 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US10940177 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US11179434 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US11771733 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US12128083 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US12186360 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US9463183 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US9616096 | Lisinopril formulations | Nov 06, 2035 | Azurity |
| Qbrelis | US9814751 | Lisinopril formulations | Nov 06, 2035 | Azurity |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Lisinopril's patents.
Latest Legal Activities on Lisinopril's Patents
Given below is the list recent legal activities going on the following patents of Lisinopril.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2024 | US9463183 |
| Patent Issue Date Used in PTA Calculation Critical
| 03 Oct, 2023 | US11771733 |
| Mail Patent eGrant Notification | 03 Oct, 2023 | US11771733 |
| Recordation of Patent Grant Mailed Critical
| 03 Oct, 2023 | US11771733 |
| Email Notification Critical
| 03 Oct, 2023 | US11771733 |
| Recordation of Patent eGrant | 03 Oct, 2023 | US11771733 |
| Patent eGrant Notification | 03 Oct, 2023 | US11771733 |
| Email Notification Critical
| 15 Sep, 2023 | US11771733 |
| Issue Notification Mailed Critical
| 13 Sep, 2023 | US11771733 |
| Dispatch to FDC | 24 Aug, 2023 | US11771733 |
Lisinopril's Family Patents
